Position in ZYME
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$1,966,816
+$1,706,054 QoQ
Shares Held
78,547
+156.3% QoQ
Ownership
0.108%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PRINCIPAL FINANCIAL GROUP INC holds $1,683,587,850 across 95 Biotechnology names. ZYME ranks #48 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
896,397 | $205,032,885 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
426,523 | $190,459,579 | |
| 3 | INSM |
INSMED Inc
|
916,464 | $149,860,192 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
1,330,415 | $98,796,617 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
120,425 | $93,045,171 | |
| 6 | GPCR |
Structure Therapeutics Inc.
|
1,753,764 | $84,531,424 | |
| 7 | CYTK |
Cytokinetics Inc
|
1,093,485 | $72,071,595 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
350,488 | $59,239,481 |
All Filings in ZYME
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,966,816 | 78,547 | Shares | Defined | 2026-05-04 | |
| 2024-06-30 | $260,762 | 30,642 | Shares | Defined | 2024-07-29 | |
| 2024-03-31 | $273,214 | 25,971 | Shares | Defined | 2024-04-29 | |
| No filing history on record for this holder in this stock. | ||||||